Latest news with #LANXESS
Yahoo
a day ago
- Business
- Yahoo
LANXESS Aktiengesellschaft (ETR:LXS) Just Released Its Half-Year Earnings: Here's What Analysts Think
Explore LANXESS's Fair Values from the Community and select yours LANXESS Aktiengesellschaft (ETR:LXS) just released its latest interim report and things are not looking great. It was a pretty negative result overall, with revenues of €3.1b missing analyst predictions by 3.4%. Worse, the business reported a statutory loss of €1.18 per share, much larger than the analysts had forecast prior to the result. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Taking into account the latest results, the current consensus, from the 14 analysts covering LANXESS, is for revenues of €6.01b in 2025. This implies a noticeable 2.3% reduction in LANXESS' revenue over the past 12 months. Per-share losses are predicted to creep up to €2.01. Yet prior to the latest earnings, the analysts had been forecasting revenues of €6.17b and losses of €1.21 per share in 2025. So it's pretty clear the analysts have mixed opinions on LANXESS after this update; revenues were downgraded and per-share losses expected to increase. Check out our latest analysis for LANXESS There was no major change to the consensus price target of €27.61, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on LANXESS, with the most bullish analyst valuing it at €38.00 and the most bearish at €20.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 4.5% by the end of 2025. This indicates a significant reduction from annual growth of 1.2% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 3.2% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - LANXESS is expected to lag the wider industry. The Bottom Line The most important thing to take away is that the analysts increased their loss per share estimates for next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. The consensus price target held steady at €27.61, with the latest estimates not enough to have an impact on their price targets. With that in mind, we wouldn't be too quick to come to a conclusion on LANXESS. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple LANXESS analysts - going out to 2027, and you can see them free on our platform here. Don't forget that there may still be risks. For instance, we've identified 1 warning sign for LANXESS that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
LANXESS Second Quarter 2025 Earnings: Misses Expectations
Explore LANXESS's Fair Values from the Community and select yours LANXESS (ETR:LXS) Second Quarter 2025 Results Key Financial Results Revenue: €1.47b (down 13% from 2Q 2024). Net loss: €45.0m (loss widened by 181% from 2Q 2024). €0.52 loss per share (further deteriorated from €0.18 loss in 2Q 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period LANXESS Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 69%. Looking ahead, revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Chemicals industry in Germany. Performance of the German Chemicals industry. The company's shares are down 5.4% from a week ago. Risk Analysis Be aware that LANXESS is showing 1 warning sign in our investment analysis that you should know about... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
12-07-2025
- Business
- Business Insider
Kepler Capital Remains a Hold on LANXESS (LNXSF)
In a report released on July 10, Martin Roediger from Kepler Capital maintained a Hold rating on LANXESS, with a price target of €29.00. The company's shares closed last Monday at $30.30. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Roediger is a 4-star analyst with an average return of 7.0% and a 52.10% success rate. Roediger covers the Basic Materials sector, focusing on stocks such as Solvay SA, Linde, and DSM-Firmenich AG. In addition to Kepler Capital , LANXESS also received a Hold from DZ BANK AG's Peter Spengler in a report issued on July 8. However, on July 2, Morgan Stanley maintained a Buy rating on LANXESS (Other OTC: LNXSF). The company has a one-year high of $36.00 and a one-year low of $22.95. Currently, LANXESS has an average volume of 1,375.
Fibre2Fashion
11-07-2025
- Science
- Fibre2Fashion
LANXESS pigments colour 3D-printed concrete at Venice Biennale
Inorganic pigments from LANXESS are opening up new design possibilities in 3D concrete printing. A current example is the concrete sculpture 'Duality of Skin and Core,' which was designed using red and black iron oxide pigments. It is currently on display in the 'Time. Space. Existence.' exhibition at the Venice Architecture Biennale. Assistant Professor Cristina Nan and architect Mattia Zucco from the Department of the Built Environment at Eindhoven University of Technology developed the concrete sculpture as an architectural experiment. The modular column was realized in collaboration with LANXESS and Dutch 3D printing specialist Vertico. LANXESS pigments are enabling new design potential in 3D concrete printing, showcased in the sculpture “Duality of Skin and Core†at the Venice Biennale. Created with red and black pigments, the modular column demonstrates sustainable design, colour integration, and digital fabrication. Research confirms Bayferrox and Colortherm pigments ensure colour quality without affecting concrete properties. The project shows how color, computer-generated patterns, and material performance can be integrated into digitally controlled manufacturing processes. This opens up new aesthetic and constructive approaches for the architecture of tomorrow. Innovative design and materiality in 3D concrete printing 'Duality of Skin and Core' reinterprets the classic architectural column. A slit-like opening in the cladding reveals the colored interior – hence the name. Until now, a monolithic, gray aesthetic has dominated comparable applications. The innovative design and manufacturing strategy significantly expands the possibilities of 3D printing with concrete. Instead of printing components in a single pass, the project pursues a modular strategy. Inspired by ancient Greek and Roman columns, the artwork consists of nine drums and four wings. Each individual element weighs less than 30 kilograms. This principle facilitates transport, enables flexible assembly, disassembly, and reuse, and thus extends the life cycle of the components – an important contribution to sustainable construction and circular design principles. LANXESS as a driver of innovation in 3D concrete printing In order to secure the potential of colored concrete in 3D printing, not only in terms of design but also in terms of technology, LANXESS is conducting research into the properties of its pigments under additive manufacturing conditions in collaboration with partners such as the Institute of Construction Materials at the Technical University of Dresden. As part of joint investigations, the partners have analyzed how Bayferrox and Colortherm pigments behave in 3D concrete printing. The results show that the pigments do not affect the concrete properties and at the same time enable high color quality and consistency. They can therefore be used without restriction for the individual coloring of the up to now mostly gray material in 3D printing. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. ALCHEMPro News Desk (HU)
Yahoo
06-06-2025
- Business
- Yahoo
MarketsandMarkets' 360Quadrants Recognizes Top Startups and SMEs in the PFAS Testing Quadrant Report 2025
DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ -- 360Quadrants has released its latest PFAS testing Startups/SMEs Companies Assessment, 2025, recognizing key players, including both global giants and emerging innovators, for their excellence in market presence, product innovation, and business strategy. The report highlights Restek Corporation, LANXESS, Evonik, and Cytiva among the top companies that are actively shaping the future of the PFAS testing Startups/SMEs Companies Assessment. The evaluation leverages 360Quadrants' proprietary methodology to map competitive positioning across 7,000+ micro markets within 10+ industries, enabling decision-makers to make strategic, data-backed vendor choices. Company Highlights in the PFAS testing Startups/SMEs Companies Assessment: Restek Corporation is a privately held company specializing in the development and manufacturing of high-performance chromatography columns and accessories. Renowned for its innovation and precision, Restek offers a broad portfolio of analytical solutions tailored for the analysis and quality monitoring of air, water, soil, food, pharmaceuticals, chemicals, and petroleum products. In addition to its chromatography products, Restek provides a comprehensive range of certified reference standards that support critical applications in environmental testing, clinical diagnostics, forensic science, toxicology, petrochemical analysis, and pharmaceutical research. Serving laboratories and research institutions around the globe, Restek is widely recognized for delivering reliable, high-quality products that meet the evolving needs of analytical science professionals. Evonik Industries AG, based in Essen, Germany, is a leading global specialty chemicals company known for delivering high-performance materials and innovative solutions across a broad range of industries, including healthcare, nutrition, coatings, agriculture, and energy. With a strong emphasis on sustainability and resource efficiency, Evonik leverages advanced research and development to drive innovation and support environmentally responsible practices. Evonik is actively pursuing the development of sustainable, fluorine-free alternatives. This includes the creation of advanced surfactants, coatings, and additives designed to replace traditional PFAS-based materials, reinforcing the company's commitment to safer, more sustainable chemical solutions. LANXESS is a specialty chemicals company headquartered in Cologne, Germany, established in 2004 as a spin-off from Bayer AG's chemicals division and select polymer operations. With a global presence spanning 32 countries, LANXESS focuses on the development, production, and marketing of high-quality chemical intermediates, additives, and consumer protection products. To explore the full quadrant report and see how companies are positioned in the PFAS testing Startups/SMEs Companies Assessment, 2025, Visit: Evaluation Criteria The vendor evaluation was conducted on over 130 companies, of which the top 10 were categorized and recognized as quadrant leaders. Factors such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the PFAS Testing Startups/Small-Medium Businesses Companies Assessment quadrant. The top criteria for product footprint evaluation included Product (Instruments, consumables, and software & services), Technique (Liquid chromatography with tandem mass spectrometry (LC-MS/MS), gas chromatography-mass spectrometry (GC-MS), NMR spectroscopy, mass spectrometry, combustion ion chromatography, enzyme-linked immunosorbent assays (ELISA), and other techniques), and Methods (EPA, DIN, ISO, ASTM, and Other methods), and Application. 360 Quadrants Scoring Methodology 360 Quadrants employs a comprehensive and transparent scoring methodology to evaluate companies. It identifies relevant evaluation criteria, collects and validates data from multiple sources, and employs an algorithm that considers parameter weights to generate scores. Normalization ensures fair comparisons, and the aggregated scores categorize solutions into quadrants such as Progressive companies, Responsive companies, Dynamic companies, and Starting blocks. This unbiased approach equips users with accurate information, empowering them to make well-informed decisions and select solutions that best suit their needs and objectives. Download Free Sample @ About 360Quadrants 360Quadrants, a specialized division of MarketsandMarkets™, delivers comprehensive quadrant analyses for various emerging technologies and markets, including start-ups. Our evaluation methodology hinges on two critical parameters: market presence and product footprint. This approach facilitates a graphical representation of competitive positioning across four key categories: leaders, contenders, innovators, and emerging companies. In addition, we meticulously classify start-ups into progressive companies, responsive companies, dynamic companies, and starting blocks. Our expertise equips organizations with insights into market leaders across over 6000 micro markets, enabling a detailed comparison of vendor capabilities and performance. At 360Quadrants, we ensure that each quadrant adheres to the highest standards, empowering our clients to navigate complex market dynamics precisely and confidently. 360Quadrants has also launched quadrants in fields such as - Material Informatics Startups/SMEs Companies Assessment, 2025, and Livestock Monitoring Startups/SMEs Companies Assessment, 2025. About MarketsandMarkets MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Ms. Sipti Banga,630 Dundee Road, Suite 430Northbrook, IL 60062USA: +1-888-600-6441Email: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
